Tim Moore Global Head, Pharmaceutical Technical Operations Biologics, Genentech a member of the Roche Group

Similar documents
Challenges in Implementing Knowledge Management within ICH Q10

Quality Metrics: A Regulatory Perspective

BioPharm. Smart Outsourcing: Strategic Alignment, Risk Management, and New Relationships

Smart Outsourcing: Strategic Alignment, Risk Management, and New Relationships

IPA Quality Forum Reflections on the Journey so far

Textvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf

GxP Auditing, Remediation, and Staff Augmentation

Supplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan

Best Practices for Selection and Oversight of CMOs for Manufacturing of Potent Products

GxP Auditing, Remediation, and Quality System Resourcing

36th Board Meeting Prioritized Action Plan (PAP) to Accelerate Management for Impact For Board Information

Process Capability and relationship to Quality management

GxP Auditing, Remediation, and Staff Augmentation

Amgen Supply Chain Segmentation The Journey to October 23, 2014

Pharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful

An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America

Q10 PHARMACEUTICAL QUALITY SYSTEM

Future of Pharmaceutical Quality and the Path to Get There

Pharma EXPO 6 9 November 2016 Chicago, IL

ICH Q8/Q8(R)

Risk Advisory Services Developing your organisation s governance for competitive advantage

An Overview of the AWS Cloud Adoption Framework

IT Governance Overview

Sponsor/CRO Partnership Optimization

Pharmaceutical Quality for 21 st Century Initiative

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges

Case Study: Validation Process Efficiency and Cost Reduction Improvements

Enterprise Asset Management. Enterprise Asset Management 1

RSA ARCHER MATURITY MODEL: AUDIT MANAGEMENT

SOLUTION BRIEF RSA ARCHER AUDIT MANAGEMENT

Overview of Amgen s CQP Commissioning and Qualification Program Steve Wisniewski Principal Compliance Consultant, CAI Past Chairman ISPE C&Q COP

PMDA Perspective: Regulatory Updates on Process Validation Standard

Portfolio Marketing. Research and Advisory Service

PAREXEL ACCESS MANAGED ACCESS PROGRAMS

4/26. Analytics Strategy

GUIDANCE NOTE FOR DEPOSIT TAKERS (Class 1(1) and Class 1(2))

Risk Management Strategy

At the Heart of Connected Manufacturing

AT&T IoT Partner Program Because pioneering is not a solo effort

Information and Communication Technologies Strategic Plan 2016/ /20

Agenda. Enterprise Risk Management Defined. The Intersection of Enterprise-wide Risk Management (ERM) and Business Continuity Management (BCM)

Stepping Into the Future of Pharmacovigilance

Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016

Quality Agreements and Managing Contract Supplier Quality

Mapping Success for Commercial Cell Therapy Manufacturing 100% 50% 0% 100% 50% 0% 100% 50% Realization

Quality Implementation Working Group on Q8, Q9 and Q10 Questions & Answers

Risk Management in Drug Product Manufacturing with Emphasis on Batch Documentation/Execution

Quality Systems. Indian Pharmaceutical Alliance. Advanced GMP Workshops 2017

ISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. Need systems approach to pharmaceutical manufacturing

Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario

Communication Business Partner PHC CoE

Principal approach to CPV :

Multisource Management in the Cloud Age Keys to MSI and SIAM success in Hybrid IT environments

IT Management & Governance Tool Assess the importance and effectiveness of your core IT processes

Application of enhanced process and product knowledge to facilitate the lifecycle

WHITE PAPER. Guiding principles and dimensions of testing transformation

Trinity College Dublin QP Forum 2017 Tuesday 25 th April

Identity and Access Management. Program Primer

Enabling technology for success

Quality Risk Management (ICH Q9): WHO Model for Sustainable Quality Medicines

Integration of Risk Management into Product Strategy and Portfolio. Lori Richter Senior Consultant: QRM and Quality Systems ValSource, LLC

WORLD-CLASS AUDIT REGULATION November Big Four Inspections Report.

Sales & Operations Planning: An Introduction

An Industry Perspective: The Complexity of Postapproval CMC Changes and Proposed Regulatory Strategies. SPEAKER: Suzanne Murray Biogen

WHITE PAPER The Three Stages of Harnessing Inventory in the S&OP Journey. Executive Summary

ISO Your implementation guide

Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products

Ready to help lead a dynamic team that is reshaping health care shared services and how they re delivered?

How a project approach will build change management capability across your organization

Foundations for an Effective Quality Relationship with Contract Manufacturers

KINGSMANN CARE GROUP

Seamless Integration of ASTM E2500, Annex 15, FDA Process Validation Guideline and Chinese GMP in Large CapEx Project in China Daniel Nilsson

QP Forum Quality Risk Management & Quality Metrics Ann McGee, Principal Consultant, MPI April your partner in compliance

How can regulatory affairs drive greater value for the patient and for the business?

QbD Concepts Applied to Qualification and Transfer of Analytical Methods

Translate stakeholder needs into strategy. Governance is about negotiating and deciding amongst different stakeholders value interests.

WHO guidelines on quality risk management

Helping unlock growth opportunities worldwide

Investor Day Client-driven market approach. Doug McCuaig, EVP, Global Client Transformation Services. CGI Group Inc.

Back to School for Business Services how to get it right?

Developing a Robust Quality System to Assure Data Integrity

Manufacturing Execution Systems (MES) Services. An overview of CGI s capabilities and ready-to-buy services

The State of QbD in the Biopharmaceutical Industry Conference

Maturity Modeling: A Strategic Roadmap to Improve Your Business Continuity Program

Business Case for Value Realization During Implementation Delivering Projects on Time, on Budget, and on Value

CSR / Sustainability Governance and Management Assessment By Coro Strandberg President, Strandberg Consulting

Policy Administration Transformation

Managing QbD From A CMO Perspective

Global Business Services. Continuous Planning. Summary. January, Financial Management. Copyright IBM Corporation 2002

The ShawCor Manufacturing System. SMS Leadership Development

Statement A: Approved for public release, distribution is unlimited (5 MAY 2015)

Guidance for Industry Process Validation: General Principles and Practices. F. Hoffman-La Roche, Ltd.

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

A roadmap for maximizing supply chain effectiveness

Cisco s Digital Transformation Supply Chain for the Digital Age

The Robots Are Rising

Supply Management Three-Year Strategic Plan

Clinical Performance Metrics & Benchmarking Summit

Transcription:

Ensuring the Supply of Quality Biopharmaceuticals: Integrated Manufacturing Network & Continual Improvement of Manufacturing Process Tim Moore Global Head, Pharmaceutical Technical Operations Biologics, Genentech a member of the Roche Group

Presentation Overview Our Biologics Network Complex and Evolving Operating Environment Strategies and Tactics to Address Environment Closing Thoughts 3

Our Biologics Network Biologics is made up of 11 internal and 37 external sites Hillsboro Mannheim Kaiseraugst Penzberg Vacaville S. San Francisco Basel DS Basel DP Oceanside Singapore 6 DS Sites 5 DP Sites 37 CMO Sites (5 DS, 10 DP, 3 EM, 19 Combo/Device) 4 we manufacture over 20 products that serve our patients globally 4

Complex and Evolving Operating Environment There are many complexities to get to the final product Technology Scale-up and Transfers 5

Strategies and Tactics to Address Environment Supply Reliability Ability to continuously & reliably supply medicines to patients Supply Reliability Dual / Multiple Sourcing Agility Capacity Risk Mitigation Inventory Business Continuity Management Risk Assessment & Management focus on prevention Process Robustness basis for resilient supply Manufacturing Network: Combination of internal and external partners to achieve pillars of supply chain resiliency 6

Strategies and Tactics to Address Environment Manufacturing Strategy Operational framework for aligned internal & external sourcing Launch Growth Steady State Decline Agility Agility & Reliability & Efficiency Efficiency Reliability Manufacturing volume Launch Loss of Exclusivity Internal Manufacturing External Manufacturing Divest Right Type Right Asset Right Time Ensure the Network Can Respond to Demand Volatility 1.Agile capacity target 80% internal utilization 2.Ability to dual source and maintain inventory targets Maintain a Reliable Asset Base at Defined Utilization 1. Optimize the size, shape and expertise of each site to ensure fit-for-purpose 2. Base Load - external manufacturing network Implement Sourcing Solutions Applicable to Product Life Cycle 1. Launch products internally where capability & capacity exist 2. Outsource mature products, to create available capacity 7

Strategies and Tactics to Address Environment Biologics Manufacturing Plan Multi-year plan for creating an Agile and Robust Manufacturing Network Near Term (<12 months) Increased run rates in Basel, Singapore and Oceanside facilities Debottlenecking efforts in South San Francisco, Penzberg, Basel and Singapore Continue to transfer existing products into new Drug Product plants in Hillsboro Oregon and Kaiseraugst Switzerland Mid Term (1-3 years) Strategic Investments in Internal Drug Substance Manufacturing Strategic Investments in External Drug Substance and Drug Product Manufacturing Long Term (4+ years) Internal Antibody Drug Conjugation Manufacturing Additional investment in internal Drug Product Manufacturing 8

Strategies and Tactics to Address Environment Biologics Manufacturing Plan Contract Manufacturing Operations (CMO) Partnership and Oversight Organization & Governance Establish one Biologics network approach Joint management teams at senior and operational levels. Lifecycle management: Select-Implement-Manage-Decommission Qualification of new CMOs Contract Quality Requirements (CQR s) including Quality Risk Management (QRM), Quality Agreements, Tech Transfers CMO selection and filing readiness requires approval by Head of OU Quality GMP audits by Corporate Inspection Management Establish Key Strategic Relationships Co-investment; Long term supply commitment (base-load CMO s); Alignment of Contract Quality Requirements; Quality Improvement Plans Ongoing oversight Dedicated team, Person in Plant, as appropriate Key changes, deviations, and final batch disposition managed by Genentech/Roche Issues escalated to Quality Review Board (QRB) and regular QSMR 9

Strategies and Tactics to Address Environment Technical Product Management (TPM) Cross-functional product management teams created to provide strategic leadership for all commercial products Benefits Proactive and strategic view Integrated product portfolio visibility and oversight Product and process capability Supply chain and product quality health Quality inputs assessed throughout the product lifecycle 10

Strategies and Tactics to Address Environment Manufacturing Process - Use of QbD in Development Advantage for Overall Product Quality Life Cycle Risk Management Quality by Design (QbD) can be a highly effective global driver of change in the industry providing: Enhanced level of assurance of product quality and process robustness More rapid resolution of manufacturing discrepancies The foundation for continued improvement and risk-based regulatory action Ultimate goal is a process that sustains quality supply Gazyva, the 1 st biologic product approved with a Design Space High incentive for regulators and the industry to work together to realize the overall benefits and objectives of QbD, and to enable the vision of risk-based, lifecycle management 11

Strategies and Tactics to Address Environment Leveraging Engrained Quality Increasing compliance sustainability and reliable quality supply Optimize PQS and IT Systems / Business Process Integration (PQS Realization/Monitoring, IT Roadmap) Track & Trend and improve process capability (Quality by Design, Six Sigma, Post Approval Lifecycle Management) Continue to develop leadership & technical competencies and depth (Quality Certification Program (QCP), Investigator Certification Program (ICP)) Advance compliance sustainability and proactive risk management (Technical Product Management (TPM), Quality Risk Management (QRM)) Continue to enhance quality ownership, and assess and advance quality culture (Mindset training & tools, Senior Management Engagement) 12

Key Take-Aways The ability to meet global supply demand requires. Robust Quality Systems Network of internal and external sites Multi-Year plan to build agility and flexibility Dual sourced, reliable Supply Chain strategy It s a journey that takes focus and resilience 13

Doing now what patients need next 14